Published in Neuron on November 18, 2004
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell (2011) 3.78
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature (2010) 3.41
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest (2009) 3.17
A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet (2011) 3.16
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology (2008) 2.73
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell (2014) 2.63
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol (2007) 2.54
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J (2008) 2.43
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol (2011) 2.42
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol (2009) 2.34
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics (2005) 2.31
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev (2011) 2.25
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab (2007) 2.21
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics (2006) 2.10
Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci U S A (2006) 2.08
The genetic epidemiology of neurodegenerative disease. J Clin Invest (2005) 2.08
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord (2013) 2.01
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci (2008) 1.92
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A (2005) 1.91
The role of parkin in familial and sporadic Parkinson's disease. Mov Disord (2010) 1.90
PINK1- and Parkin-mediated mitophagy at a glance. J Cell Sci (2012) 1.89
Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci U S A (2006) 1.88
Plant and animal pathogen recognition receptors signal through non-RD kinases. PLoS Pathog (2006) 1.87
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics (2006) 1.79
Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology (2013) 1.78
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med (2012) 1.75
Towards a complete resolution of the genetic architecture of disease. Trends Genet (2010) 1.75
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol (2015) 1.72
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun (2008) 1.71
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
The dictyostelium kinome--analysis of the protein kinases from a simple model organism. PLoS Genet (2006) 1.69
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J (2008) 1.68
Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet (2011) 1.68
Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med (2012) 1.67
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64
LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci (2009) 1.64
The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord (2013) 1.63
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J (2008) 1.62
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci (2007) 1.59
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A (2007) 1.58
Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci (2012) 1.58
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet (2012) 1.56
Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol (2010) 1.56
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (2008) 20.68
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genotype, haplotype and copy-number variation in worldwide human populations. Nature (2008) 12.40
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74
Genotype-imputation accuracy across worldwide human populations. Am J Hum Genet (2009) 7.28
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet (2005) 3.63
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2010) 3.00
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol (2010) 2.75
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet (2002) 2.65
Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet (2011) 2.62
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain (2005) 2.34
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One (2009) 2.23
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet (2007) 2.09
Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One (2009) 1.98
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J Immunol (2004) 1.90
Allelic heterogeneity and more detailed analyses of known loci explain additional phenotypic variation and reveal complex patterns of association. Hum Mol Genet (2011) 1.83
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet (2007) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging (2008) 1.76
Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet (2011) 1.75
Transformation of cone precursors to functional rod photoreceptors by bZIP transcription factor NRL. Proc Natl Acad Sci U S A (2007) 1.74
Alcohol-responsive genes in the frontal cortex and nucleus accumbens of human alcoholics. J Neurochem (2005) 1.73
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet (2004) 1.72
The effect of survival bias on case-control genetic association studies of highly lethal diseases. Circ Cardiovasc Genet (2011) 1.71
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain (2002) 1.70
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol (2006) 1.66
Multiple loci are associated with white blood cell phenotypes. PLoS Genet (2011) 1.65
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol (2007) 1.59
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Food selectivity in children with autism spectrum disorders and typically developing children. J Pediatr (2010) 1.58
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. Am J Hum Genet (2013) 1.55
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55